TABLE 4.
Correlation of Malignant Cases With RAS Mutations
| Histologic Diagnosis | Age, Range, y | Sex, No. | Procedure, No. | Tumor Site, No. | Tumor Size, Range, cm | LVI, No. | Molecular Alteration, No. |
|---|---|---|---|---|---|---|---|
| PTC (n = 14) | |||||||
| FV (n = 10) | 23–69 | F = 6 | T = 4 | RS = 7 | 1.7–6.3 | Focal = 3 | HRAS alone = 3 |
| M = 4 | L = 6 | LS = 3 | Ext = 1 | HRAS with others = 3 | |||
| NRAS alone = 1 | |||||||
| NRAS with others = 2 | |||||||
| KRAS with others = 1 | |||||||
| Other (n = 4)a | 34–60 | F = 4 | T = 2 | RS = 4 | 0.8–3.4 | — | NRAS alone = 2 |
| L = 2 | NRAS and MIR = 1 | ||||||
| KRAS and MIR = 1 | |||||||
| FTC (n = 4) | 33–71 | F = 4 | T = 3 | RS = 3 | 2–7.9 | Focal = 1 | KRAS alone = 1 |
| L = 1 | LS = 1 | Ext = 1 | NRAS and MIR = 3 | ||||
| HCC (n = 2) | 53–58 | F = 2 | T = 2 | RS = 2 | 0.8–1.5 | Focal = 1 | NRAS and MIR = 1 |
| NRAS and GEF = 1 | |||||||
| PDTC (n = 1) | 66 | F | T | LS | 4.8 | Ext | NRAS and TERT |
Abbreviations: Ext, extensive; F, female; FTC, follicular thyroid carcinoma; FV, follicular variant; GEF, gene expression profile; HCC, Hürthle cell carcinoma; L, lobectomy; LS, left side; LVI, lymphovascular invasion; M, male; MIR, miRNA classifier; PDTC, poorly differentiated thyroid carcinoma; PTC, papillary thyroid carcinoma; RS, right side; T, total thyroidectomy.
a
Includes cases with mixed features (follicular and solid features; n = 1), classic variant (n = 1), and papillary thyroid microcarcinoma (n = 2).